CPT code 88237 represents a laboratory service where cells from bone marrow or peripheral blood are cultured to evaluate neoplastic (cancerous) disorders. This code covers specialized cell-culture techniques used in the diagnosis and monitoring of hematologic malignancies and related cytogenetic investigations. The procedure is clinically important because cultured cells can reveal chromosomal abnormalities and morphological features that guide diagnosis, prognosis, and treatment planning across the United States.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of this code, typical sites of service, and common billing considerations. The publication summarizes benchmarking context, payer coverage patterns, and recent policy updates affecting laboratory and cytogenetic services. It also outlines the clinical context in which the service is used and highlights areas where coding clarity and documentation are important.

This national-level summary is intended for billing professionals, laboratory administrators, and policy analysts seeking an authoritative reference on CPT code 88237, its clinical role in neoplastic disorder evaluation, and the payer landscape relevant to laboratory diagnostic services.